Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 21-30 of 110 (Search time: 0.015 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2012Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemiaYin, O.; Giles, F.; Baccarani, M.; le Coutre, P.; Chiparus, O.; Gallagher, N.; Saglio, G.; Hughes, T.; Hochhaus, A.; Kantarjian, H.; Larson, R.
2012Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phaseLarson, R.; Yin, O.; Hochhaus, A.; Saglio, G.; Clark, R.; Nakamae, H.; Gallagher, N.; Demirhan, E.; Hughes, T.; Kantarjian, H.; le Coutre, P.
2010Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with ImatinibWhite, D.; Dang, P.; Engler, J.; Frede, A.; Osborn, M.; Saunders, V.; Manley, P.; Zrim, S.; Hughes, T.
2012Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitorsNieborowska-Skorska, M.; Kopinski, P.; Ray, R.; Hoser, G.; Ngaba, D.; Flis, S.; Cramer, K.; Reddy, M.; Koptyra, M.; Penserga, T.; Glodkowska-Mrowka, E.; Bolton, E.; Holyoake, T.; Eaves, C.; Cerny-Reiterer, S.; Valent, P.; Hochhaus, A.; Hughes, T.; Van der Kuip, H.; Sattler, M.; et al.
2012Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity TrialGuilhot, F.; Hughes, T.; Cortes, J.; Druker, B.; Baccarani, M.; Gathmann, I.; Hayes, M.; Granvil, C.; Wang, Y.
2011Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid LeukemiaCortes, J.; Hochhaus, A.; Hughes, T.; Kantarjian, H.
2013Which TKI? An embarrassment of riches for chronic myeloid leukemia patientsHughes, T.; White, D.
2011OCT-1 function varies with cell lineage but is not influenced by BCR-ABLEngler, J.; Zannettino, A.; Bailey, C.; Rasko, J.; Hughes, T.; White, D.
2011Do we have to kill the last CML cell?Ross, D.; Hughes, T.; Vaz de Melo, J.
2011OCT-1 as a determinant of response to antileukemic treatmentEngler, J.; Hughes, T.; White, D.